BioNTech SE (BNTX) Accounts Payables (2018 - 2025)

BioNTech SE (BNTX) has 8 years of Accounts Payables data on file, last reported at $622.6 million in Q4 2025.

• For the quarter ending Q4 2025, Accounts Payables rose 36.55% year-over-year to $622.6 million; the trailing twelve-month figure through Dec 2025 stood at $622.6 million (up 36.55% YoY), and the FY2025 full-year result was $604.3 million, up 32.54% from the prior year.
• Accounts Payables grew to $622.6 million in Q4 2025, from $467.4 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $949.3 million in Q2 2024 to a low of $32.1 million in Q1 2023.
• A 5-year average of $381.5 million and a median of $317.6 million in 2024 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables sank 76.88% in 2023 and surged 911.45% in 2024, its largest moves.
• Tracing BNTX's Accounts Payables over 5 years: stood at $183.0 million in 2021, then gained by 13.77% to $208.2 million in 2022, then jumped by 82.91% to $380.9 million in 2023, then rose by 19.71% to $456.0 million in 2024, then soared by 36.55% to $622.6 million in 2025.
• Business Quant data shows BNTX's Accounts Payables at $622.6 million in Q4 2025, $467.4 million in Q3 2025, and $570.7 million in Q2 2025.